Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles

Alexandre Ingels, Ingrid Leguerney, Paul-Henry Cournède, Jacques Irani, Sophie Ferlicot, Catherine Sebrié, Baya Benatsou, Laurène Jourdain, Stéphanie Pitre-Champagnat, Jean‐Jacques Patard, Nathalie LassauScientific 2020 · DOI

Abstract

Recent treatment developments for metastatic renal cell carcinoma offer combinations of immunotherapies or immunotherapy associated with tyrosine kinase inhibitors (TKI). There is currently no argument to choose one solution or another. Easy-to-use markers to assess longitudinal responses to TKI are necessary to determine when to switch to immunotherapies. These new markers will enable an earlier adaptation of therapeutic strategy in order to prevent tumor development, unnecessary toxicity and financial costs. This study evaluates the potential of ultrasound molecular imaging to track the response to sunitinib in a clear cell renal carcinoma model (ccRCC). We used a patient-derived xenograft model for this imaging study. Mice harboring human ccRCC were randomized for sunitinib treatment vs. control. The tumors were imaged at days 0, 7, 14 and 28 with ultrasound molecular imaging. Signal enhancement was quantified and compared between the two groups after injections of non-targeted microbubbles and microbubbles targeting VEGFR1 and FSHR. The tumor growth of the sunitinib group was significantly slower. There was a significantly lower expression of both VEGFR-1 and FSHR molecular ultrasound imaging signals in the sunitinib group at all times of treatment (Days 7, 14 and 28). These results confirm the study hypothesis. There was no significant difference between the 2 groups for the non-targeted microbubble ultrasound signal. This study demonstrated for the first time the potential of VEGFR1 and FSHR, by ultrasound-based molecular imaging, to follow-up the longitudinal response to sunitinib in ccRCC. These results should trigger developments for clinical applications.

Introduction

Renal Cell Carcinoma (RCC) treatment has become increasingly complex, often requiring a choice between immunotherapies and tyrosine kinase inhibitors (TKIs) like sunitinib. Currently, clinical decisions are largely guided by the RECIST criteria, which measure physical tumor shrinkage. However, tumor volume is a "lagging indicator"—biological changes often precede physical size reduction by weeks or months. Relying solely on volume measurements can lead to patients remaining on ineffective, toxic, or expensive treatments longer than necessary.

There is a critical need for "leading indicators"—biomarkers capable of detecting molecular responses within days. This study explores the potential of ultrasound molecular imaging (USMI) using targeted microbubbles to track therapeutic response in a clear cell renal carcinoma (ccRCC) model.

Methods and Materials

The researchers utilized a Patient-Derived Xenograft (PdX) model, where human ccRCC tissue was implanted into mice to preserve the complex architecture of the original human tumor. The study involved 33 mice grafted with tumors derived from three different patients.

Experimental timeline and study protocol showing the longitudinal imaging schedule and treatment groups.

The core technology, Ultrasound Molecular Imaging (USMI), works as follows:

  1. Targeted Microbubbles: Gas-filled microbubbles were functionalized with antibodies targeting VEGFR1 (a marker of angiogenesis) and FSHR (Follicle Stimulating Hormone Receptor, a specific marker on tumor vessels).
  2. Destruction-Replenishment: High-intensity ultrasound pulses were used to "pop" bubbles within the tumor. The subsequent replenishment of targeted bubbles sticking to the vessel walls was measured to quantify protein expression.
  3. Experimental Design: Mice were randomized into a sunitinib-treated group (80 mg/kg) and a placebo group. Imaging (USMI and 7T MRI) was performed at Days 0, 7, 14, and 28. Non-targeted (NT) microbubbles served as a control for general blood flow changes.

Results

The study demonstrated that molecular signals for VEGFR1 and FSHR decreased significantly in treated tumors as early as Day 7, even when volume changes were minimal.

Ultrasound molecular imaging (USMI) quantification using the destruction-replenishment technique, showing the time-intensity curve and corresponding B-mode/contrast images.

Key Findings:

  • Tumor Growth: Sunitinib significantly slowed tumor growth compared to the control ($p = 0.0009$), although stabilization was more common than immediate shrinkage.
  • Early Molecular Response: Both VEGFR1 and FSHR signals were significantly lower in the sunitinib group at all time points (Days 7, 14, and 28). At Day 7, p-values were 0.021 for VEGFR1 and 0.046 for FSHR. By Day 14, the difference in FSHR expression was even more pronounced ($p = 0.001$).
  • Specificity: Non-targeted microbubbles showed no significant difference between groups, confirming that the observed signal drop was due to reduced target protein expression rather than just decreased blood flow.
  • Predictive Power: VEGFR1 expression at Day 7 was significantly lower in "responder" mice compared to "non-responders" ($p = 0.018$), suggesting potential for early identification of treatment failure.

Discussion and Conclusion

This study is the first to demonstrate that FSHR can serve as a specific target for USMI to monitor RCC. Unlike some markers, FSHR is selectively expressed on tumor vessels, making it a highly specific indicator of cancer activity.

Several limitations must be addressed before clinical translation. The use of biotin-streptavidin links for antibody attachment is unsuitable for human use due to potential immunogenicity; future clinical versions will require direct covalent bonding. Additionally, the 2D nature of the ultrasound imaging may not fully capture the heterogeneity of kidney tumors, suggesting a need for 3D USMI. While the results are promising, the small number of non-responder mice (n=4) necessitates larger studies to confirm the predictive value of these molecular markers.

In conclusion, VEGFR1 and FSHR-targeted USMI provides a non-invasive, early-stage assessment of TKI response in RCC, offering a path toward more personalized and timely therapeutic adjustments in clinical practice.

Summary updated

Abstract

Recent treatment developments for metastatic renal cell carcinoma offer combinations of immunotherapies or immunotherapy associated with tyrosine kinase inhibitors (TKI). There is currently no argument to choose one solution or another. Easy-to-use markers to assess longitudinal responses to TKI are necessary to determine when to switch to immunotherapies. These new markers will enable an earlier adaptation of therapeutic strategy in order to prevent tumor development, unnecessary toxicity and financial costs. This study evaluates the potential of ultrasound molecular imaging to track the response to sunitinib in a clear cell renal carcinoma model (ccRCC). We used a patient-derived xenograft model for this imaging study. Mice harboring human ccRCC were randomized for sunitinib treatment vs. control. The tumors were imaged at days 0, 7, 14 and 28 with ultrasound molecular imaging. Signal enhancement was quantified and compared between the two groups after injections of non-targeted microbubbles and microbubbles targeting VEGFR1 and FSHR. The tumor growth of the sunitinib group was significantly slower. There was a significantly lower expression of both VEGFR-1 and FSHR molecular ultrasound imaging signals in the sunitinib group at all times of treatment (Days 7, 14 and 28). These results confirm the study hypothesis. There was no significant difference between the 2 groups for the non-targeted microbubble ultrasound signal. This study demonstrated for the first time the potential of VEGFR1 and FSHR, by ultrasound-based molecular imaging, to follow-up the longitudinal response to sunitinib in ccRCC. These results should trigger developments for clinical applications.
BibTeX
@inproceedings{ingels2020ultrasound,
  author = {Alexandre Ingels and Ingrid Leguerney and Paul-Henry Cournède and Jacques Irani and Sophie Ferlicot and Catherine Sebrié and Baya Benatsou and Laurène Jourdain and Stéphanie Pitre-Champagnat and Jean‐Jacques Patard and Nathalie Lassau},
  title = {{Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-020-64433-2},
}
Figure